Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Animal Health Bimeda Launches Gamrozyne for BRD, SRD, Ovine Foot Rot
NEWS & BLOGS IMAGES (77)

Bimeda Launches Gamrozyne for BRD, SRD, Ovine Foot Rot

16th November 2026

Bimeda has launched Gamrozyne, a gamithromycin-based single-dose macrolide antibiotic for the treatment and metaphylaxis of bovine respiratory disease (BRD), treatment of swine respiratory disease (SRD) and treatment of foot rot in sheep. Reported on 11 November 2026, the UK launch positions Gamrozyne as the first and only bioequivalent gamithromycin product, extending Bimeda’s farm animal antibiotic portfolio and intensifying commercial dynamics across the UK and Irish livestock therapeutic market.


Gamrozyne is a fast- and long-acting macrolide antibiotic delivered as a single-dose treatment. The active ingredient is rapidly absorbed following administration and achieves sustained concentrations in target tissues, supporting its use in the management of susceptible bacterial infections across cattle, pigs and sheep. Rachel Mallet, Technical and Commercial Vet for Bimeda UK, positioned the product around the ongoing challenge of respiratory disease and lameness to livestock health and welfare, flagging therapeutic lung concentrations reached just 30 minutes after administration. The accumulation effect provides prolonged activity while inflamed tissues return to normal, with Bimeda citing prevention of immediate reoccurrence as a core clinical advantage.

The commercial opportunity rests on the substantial addressable UK and Irish farm animal antimicrobial market, where BRD alone remains one of the most frequently treated conditions across beef and dairy production systems. SRD represents a similar commercial priority across the UK pig sector, while ovine foot rot continues to drive substantial antibiotic usage across the UK sheep flock. Gamithromycin has been one of the dominant long-acting macrolide actives for farm animal respiratory disease since originator launch, and the arrival of bioequivalent generic competition typically compresses pricing and improves procurement options for independent and group veterinary buyers alike. The launch also aligns with the broader UK farm animal antimicrobial stewardship agenda, where single-dose macrolides supporting metaphylactic protocols reduce total treatment courses and simplify on-farm administration compared with multi-dose regimens. Bimeda’s expanding UK farm animal portfolio positions the company as an increasingly notable player in the generic livestock pharmaceutical category.


The commercial signal is a maturing UK farm animal antibiotic category where bioequivalent macrolide entrants are reshaping pricing and procurement dynamics while supporting ongoing antimicrobial stewardship goals. Veterinary group procurement and independent farm vet uptake anchor the early commercial trajectory. Expect sustained generic farm animal pharmaceutical competition and continued focus on single-dose macrolide stewardship through 2027.

 

For the latest updates and in-depth insights into the world of Animal Health, including breakthrough treatments, industry trends, and regulatory news, contact Luca Sedicina today! 

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.

wpChatIcon
wpChatIcon